newdrugapprovals.org
Glenmark’s Enrollment Begins of First Patient in Phase II Vatelizumab (GBR 500) Trial in Relapsing Remitting Multiple Sclerosis
Enrollment Begins of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis Glenmark outlicensed Vatelizumab (GBR 500) to Sanofi for all indications in 2011 Mumbai –…